Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Adaptimmune Therapeutics Plc ADR’s stock clocked out at $0.13, down -12.90% from its previous closing price of $0.15. In other words, the price has decreased by -$12.90 from its previous closing price. On the day, 34.55 million shares were traded. ADAP stock price reached its highest trading level at $0.159 during the session, while it also had its lowest trading level at $0.1309.
Ratios:
To gain a deeper understanding of ADAP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.52.
On June 26, 2025, Mizuho Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $0.50.
On July 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $4.H.C. Wainwright initiated its Buy rating on July 30, 2024, with a $4 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 02 ’25 when Wood Gavin sold 96,000 shares for $0.01 per share. The transaction valued at 950 led to the insider holds 0 shares of the business.
Gavin Wood bought 16,000 shares of ADAP for $942 on Sep 02 ’25. On Aug 28 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 207,000 shares for $0.01 each. As a result, the insider received 2,091 and left with 986,352 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 35437400 and an Enterprise Value of 235243392. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.54. Its current Enterprise Value per Revenue stands at 3.614 whereas that against EBITDA is -1.714.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.37, which has changed by -0.85258526 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $0.96, while it has fallen to a 52-week low of $0.04. The 50-Day Moving Average of the stock is 52.51%, while the 200-Day Moving Average is calculated to be -57.40%.
Shares Statistics:
It appears that ADAP traded 77.79M shares on average per day over the past three months and 50660320 shares per day over the past ten days. A total of 265.05M shares are outstanding, with a floating share count of 255.41M. Insiders hold about 3.64% of the company’s shares, while institutions hold 27.58% stake in the company. Shares short for ADAP as of 1757894400 were 23052335 with a Short Ratio of 0.30, compared to 1755216000 on 11073333. Therefore, it implies a Short% of Shares Outstanding of 23052335 and a Short% of Float of 10.5299994.
Earnings Estimates
. The current market rating for Adaptimmune Therapeutics Plc ADR (ADAP) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.47 and -$0.47 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $12.31M. It ranges from a high estimate of $15.4M to a low estimate of $9.03M. As of. The current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $40.9MFor the next quarter, 4 analysts are estimating revenue of $15.23M. There is a high estimate of $20.1M for the next quarter, whereas the lowest estimate is $9.7M.
A total of 1 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $40.4M, while the lowest revenue estimate was $40.4M, resulting in an average revenue estimate of $40.4M. In the same quarter a year ago, actual revenue was $178.03MBased on 4 analysts’ estimates, the company’s revenue will be $64.09M in the next fiscal year. The high estimate is $85M and the low estimate is $41.4M.
